150 related articles for article (PubMed ID: 33638627)
1. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
Can PK; Etikan P; Degirmentepe EN; Kocaturk E
Asian Pac J Allergy Immunol; 2024 Jun; 42(2):132-137. PubMed ID: 33638627
[TBL] [Abstract][Full Text] [Related]
2. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
Salman A; Demir G; Bekiroglu N
Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
[TBL] [Abstract][Full Text] [Related]
3. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
Kolkhir P; Laires PA; Salameh P; Asero R; Bizjak M; Košnik M; Dissemond J; van Doorn M; Hawro T; Kasperska-Zajac A; Zajac M; Kocatürk E; Peter J; Parisi CAS; Ritchie CA; Kulthanan K; Tuchinda P; Fomina D; Kovalkova E; Khoshkhui M; Kouzegaran S; Papapostolou N; Du-Thanh A; Kamegashira A; Meshkova R; Vitchuk A; Bauer A; Grattan C; Staubach P; Bouillet L; Giménez-Arnau AM; Maurer M; Weller K
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):610-620.e5. PubMed ID: 36481420
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
5. Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life.
Larrea-Baca I; Gurpegui-Resano M
Enferm Clin; 2017; 27(6):361-368. PubMed ID: 28457893
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
Cakmak ME; Yeğit OO; Öztop N
Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
10. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
11. Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria.
Moñino-Romero S; Kolkhir P; Ohanyan T; Szépfalusi Z; Weller K; Metz M; Scheffel J; Maurer M; Altrichter S
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):167-174. PubMed ID: 37641982
[TBL] [Abstract][Full Text] [Related]
12. Does omalizumab use in chronic spontaneous urticaria results in improvement in sexual functions?
Durmaz K; Ataseven A; Temiz SA; Isik B; Dursun R
J Cosmet Dermatol; 2022 Oct; 21(10):4877-4881. PubMed ID: 35184358
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM
Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066
[TBL] [Abstract][Full Text] [Related]
14. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
15. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
16. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
17. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
18. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
[TBL] [Abstract][Full Text] [Related]
19. Stressful life events, psychiatric comorbidities and serum neuromediator levels in patients with chronic spontaneous urticaria treated with omalizumab.
Elçin A; Ayla G; Tuba Saadet Deveci B; Özlem G; Murat Ö; Ahmet Selim B; Behçet C
Allergol Immunopathol (Madr); 2024; 52(3):1-7. PubMed ID: 38721949
[TBL] [Abstract][Full Text] [Related]
20. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.
Ferrer M; Giménez-Arnau A; Saldana D; Janssens N; Balp MM; Khalil S; Risson V
J Allergy Clin Immunol Pract; 2018; 6(4):1191-1197.e5. PubMed ID: 29655772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
